Docking and Synthesis of a series of 1-(naphthalen-1- ylmethyl)-2-(pyridin-2-yl)-1H-benzo[d]imidazole derivatives designed as novel CB1 cannabinoid ligands.

Docking and Synthesis of a series of 1-(naphthalen-1- ylmethyl)-2-(pyridin-2-yl)-1H-benzo[d]imidazole derivatives designed as novel CB1 cannabinoid ligands.

Mella-Raipán, J.; Lagos, C. F.; Romero-Parra; Espinosa-Bustos, C J.; Pessoa- Mahana, H.; Recabarren-Gajardo, G.; Pessoa-Mahana, C. D.

Abstract:

The benzimidazole system has been focus of our attention owing to their affinity to CB2 cannabinoid receptors. However there are few reports of their CB1 receptors affinity. A preliminary screening of our library of benzimidazole derivatives yielded the hit compound C6 (figure1), a potent cannabinoid ligand. This molecule is structurally related to WIN 55212-2, a well know CB1 receptor agonist. In order to generate new CB1 ligands with a benzimidazole framework we made a docking study on a CB1 model, and we identified four possible zones of chemical modification (figure 1). Following this criteria we synthesized a series of 48 molecules which are being currently biologically evaluated (binding assays).

The benzimidazole system has been focus of our attention owing to their affinity to CB2 cannabinoid receptors. However there are few reports of their CB1 receptors affinity. A preliminary screening of our library of benzimidazole derivatives yielded the hit compound C6 (figure1), a potent cannabinoid ligand. This molecule is structurally related to WIN 55212-2, a well know CB1 receptor agonist. In order to generate new CB1 ligands with a benzimidazole framework we made a docking study on a CB1 model, and we identified four possible zones of chemical modification (figure 1). Following this criteria we synthesized a series of 48 molecules which are being currently biologically evaluated (binding assays).

Palavras-chave:

DOI: 10.5151/chempro-14bmos-R0233-1

Referências bibliográficas

• [1] 1Cichero E, Cesarini S, Mosti L, Fossa P. J Mol Model. 2010;16(9):1481-98
• [2] 2Pagé D, et al. Bioorg Med Chem Lett. 2008;18(13):3695-700
• [3] 3Verbist BM, De Cleyn MA, Surkyn M, Fraiponts E, Aerssens J, Nijsen MJ, Gijsen HJ.Bioorg Med Chem Lett. 2008;18(8):2574-9
• [4] 4PATENT WO/2007/120101
• [5] 5 Katherine A. Araya, C. David Pessoa Mahana, Luis G. González. European Journal of Pharmacology 572 (2007) 32–39. 6Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR.Journal of Pharmacology and Experimental Therapeutics. 1992; 263(3):1118-1126

Como citar:

Mella-Raipán, J.; Lagos, C. F.; Romero-Parra, ; Espinosa-Bustos, C J.; Pessoa- Mahana, H.; Recabarren-Gajardo, G.; Pessoa-Mahana, C. D.; "Docking and Synthesis of a series of 1-(naphthalen-1- ylmethyl)-2-(pyridin-2-yl)-1H-benzo[d]imidazole derivatives designed as novel CB1 cannabinoid ligands.", p-233-234. In: In Blucher Chemistry Proceedings, São Paulo, v. 1, n. 1, Setembro.2013. São Paulo: Blucher, 2013.
ISSN 23184043, DOI 10.5151/chempro-14bmos-R0233-1